The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology

硝酸盐/亚硝酸盐和共轭亚油酸补充剂对肥胖哮喘病理的影响

基本信息

项目摘要

Obesity is an asthma comorbidity associated with increased exacerbation rates and greater healthcare utilization by mechanisms that are not explained by increases in Type 2 helper T cell (Th2)-related biomarkers of airway inflammation associated with atopic asthma. In addition to an altered immune response in the lung (Th1/Th17) obese asthmatics are also plagued by the low-grade, chronic, systemic inflammation attributed to adipocyte secretion of pro-inflammatory chemokines and cytokines. Also contributing to systemic inflammation is the uncoupling of nitric oxide synthase (NOS) by the arginine (Arg) metabolite, asymmetric dimethyl arginine (ADMA). Low Arg/ADMA ratios are correlated with increasing body mass index and the resulting lower fractional exhaled nitric oxide (FeNO). NOS uncoupling leads to low nitric oxide bioavailability and an increase in superoxide anion production, thus contributing to the overall oxidative environment. The objective of this study is to characterize the effects of the dietary supplements nitrate (NO3-) and nitrite (NO2-) (NOx) and conjugated linoleic acid (cLA) on airway hyperresponsiveness and inflammation in obese asthmatics. Epidemiological and clinical studies using NOx or cLA (individually) supplementations have reported on their benefits in relation to disease pathologies including cardiovascular disease and metabolic disorder. A recent pilot study we conducted demonstrated the formation of the electrophilic fatty acid, nitro-cLA (NO2-cLA) from NOx + cLA supplementation in healthy subjects at concentrations ~3X endogenous basal levels. Importantly, these levels are within a dose range that exerts systemic effects in preclinical animal models. This occurs because nitroalkene fatty acids mediate anti-inflammatory signaling actions via post translational modification of key transcriptional regulatory proteins and enzymes. These effects have been demonstrated with NO2-cLA in animal and cell culture models and safety has been demonstrated using a synthetic homolog nitro-oleic acid in FDA-approved phase 1 clinical trials. Since the individual dietary constituents NO3-, NO2-, and cLA are all associated with decreased risk of metabolic syndrome symptoms and NO2-cLA is a modulator of inflammation, it is hypothesized that obese asthmatics treated with NO3- + NO2- (NOx) + cLA will manifest improved FeNO and reduced airway hyperresponsiveness and inflammation. This hypothesis will be tested by pursuing two Specific Aims: Aim 1: Improve airway .NO bioavailability and airway hyperresponsiveness with NOx + cLA treatment. Aim 2: Determine if NOx + cLA reduce the systemic and airway inflammation that contributes to the obese asthmatic phenotype. FeNO and nitrosyl hemoglobin, inflammatory cytokines and chemokines, NO2-cLA, and markers of oxidative stress will be measured as well as clinical markers of asthma including airway hyperresponsiveness and the asthma control test. Positive clinical outcomes using NOx + cLA dietary supplementation provides a complementary and integrative health intervention as well as a novel therapeutic strategy for targeting the obese asthmatic pathology.
肥胖是一种哮喘合并症,与加重率增加和更多的医疗保健相关 2型辅助性T细胞(Th 2)相关生物标志物增加无法解释的机制的利用 与过敏性哮喘相关的气道炎症除了肺部免疫反应的改变 (Th1/Th 17)肥胖哮喘患者还受到归因于哮喘的低度、慢性、全身性炎症的困扰。 脂肪细胞分泌促炎趋化因子和细胞因子。也会导致全身性炎症 是精氨酸(Arg)代谢产物不对称二甲基精氨酸对一氧化氮合酶(NOS)的解偶联 (ADMA)。低Arg/ADMA比值与体重指数增加相关, 呼出气一氧化氮分数(FeNO)。NOS解偶联导致一氧化氮生物利用度低, 在超氧阴离子的生产,从而有助于整体氧化环境。的目的 研究是为了表征膳食补充剂硝酸盐(NO3-)和亚硝酸盐(NO2-)(NOx)的影响, 共轭亚油酸(cLA)对肥胖哮喘患者气道高反应性和炎症的影响。 使用NOx或cLA(单独)表征的流行病学和临床研究已经报道了其 与包括心血管疾病和代谢紊乱在内的疾病病理学相关的益处。最近的一 我们进行的初步研究表明,亲电脂肪酸,硝基-cLA(NO2-cLA)的形成, 健康受试者中浓度约为内源性基础水平3倍的NOx + cLA补充。重要的是, 这些水平在临床前动物模型中发挥全身作用的剂量范围内。发生这种情况 因为硝基烯烃脂肪酸通过翻译后修饰介导抗炎信号传导作用 关键的转录调节蛋白和酶。这些效应已在NO2-cLA中得到证实 在动物和细胞培养模型中,使用合成同系物硝基油酸 在FDA批准的第一阶段临床试验中。由于单个膳食成分NO3-、NO2-和cLA都是 与代谢综合征症状风险降低相关,NO2-cLA是炎症调节剂, 假设用NO3- + NO2-(NOx)+ cLA治疗的肥胖哮喘患者将表现出改善, FeNO和降低气道高反应性和炎症。这一假设将由以下人员进行检验: 追求两个具体目标:目标1:改善气道NO生物利用度和气道高反应性, NOx + cLA处理。目的2:确定NOx + cLA是否减少全身和气道炎症, 导致了肥胖型哮喘。FeNO和亚硝基血红蛋白,炎性细胞因子和 将测量趋化因子、NO2-cLA和氧化应激标志物以及哮喘的临床标志物 包括气道高反应性和哮喘控制测试。使用NOx + cLA的积极临床结局 膳食补充剂提供了一种补充和综合的健康干预措施, 针对肥胖哮喘病理的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stacy Lynn Gelhaus其他文献

Stacy Lynn Gelhaus的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stacy Lynn Gelhaus', 18)}}的其他基金

An Exploris 240 for Metabolomics
适用于代谢组学的 Exploris 240
  • 批准号:
    10412402
  • 财政年份:
    2022
  • 资助金额:
    $ 19.25万
  • 项目类别:
LIMA: Lipid anti-Inflammatory Mediators in Asthma to reduce airway hyperresponsiveness in obese asthmatics
LIMA:哮喘中的脂质抗炎介质可减少肥胖哮喘患者的气道高反应性
  • 批准号:
    10369934
  • 财政年份:
    2022
  • 资助金额:
    $ 19.25万
  • 项目类别:
LIMA: Lipid anti-Inflammatory Mediators in Asthma to reduce airway hyperresponsiveness in obese asthmatics
LIMA:哮喘中的脂质抗炎介质可减少肥胖哮喘患者的气道高反应性
  • 批准号:
    10720482
  • 财政年份:
    2022
  • 资助金额:
    $ 19.25万
  • 项目类别:
The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology
硝酸盐/亚硝酸盐和共轭亚油酸补充剂对肥胖哮喘病理的影响
  • 批准号:
    9297207
  • 财政年份:
    2016
  • 资助金额:
    $ 19.25万
  • 项目类别:
Defining PAH-mediated carcinogenesis in lung: CYP metabolism and B[a]P transport
定义 PAH 介导的肺癌致癌作用:CYP 代谢和 B[a]P 转运
  • 批准号:
    7502209
  • 财政年份:
    2007
  • 资助金额:
    $ 19.25万
  • 项目类别:
Defining PAH-mediated carcinogenesis in lung: CYP metabolism and B[a]P transport
定义 PAH 介导的肺癌致癌作用:CYP 代谢和 B[a]P 转运
  • 批准号:
    7679487
  • 财政年份:
    2007
  • 资助金额:
    $ 19.25万
  • 项目类别:
Defining PAH-mediated carcinogenesis in lung: CYP metabolism and B[a]P transport
定义 PAH 介导的肺癌致癌作用:CYP 代谢和 B[a]P 转运
  • 批准号:
    7406263
  • 财政年份:
    2007
  • 资助金额:
    $ 19.25万
  • 项目类别:

相似国自然基金

相似海外基金

New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
  • 批准号:
    23K16058
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A novel mechanism of insulin resistance mediated by uric acid metabolism in adipocytes
脂肪细胞尿酸代谢介导胰岛素抵抗的新机制
  • 批准号:
    23K10969
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
肥大脂肪细胞作为乳腺癌进展的生物物理介质
  • 批准号:
    10751284
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
Elucidation of mechanisms for conversion of adipocytes to cancer-associated fibroblasts in osteosarcoma microenvironment
阐明骨肉瘤微环境中脂肪细胞转化为癌症相关成纤维细胞的机制
  • 批准号:
    23K19518
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Study on UCP-1 independent metabolic regulation by brown adipocytes
棕色脂肪细胞对UCP-1独立代谢调节的研究
  • 批准号:
    23K18303
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Development of adipocytes for gene therapy that avoids cellular stress due to overexpression of therapeutic proteins
开发用于基因治疗的脂肪细胞,避免因治疗蛋白过度表达而造成的细胞应激
  • 批准号:
    23H03065
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of bitter taste receptors in adipocytes and hepatocytes
脂肪细胞和肝细胞中苦味受体的功能分析
  • 批准号:
    23K05107
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosis
脂肪细胞中的 NKA/CD36 信号传导促进氧化应激并驱动动脉粥样硬化的慢性炎症
  • 批准号:
    10655793
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
  • 批准号:
    23K05594
  • 财政年份:
    2023
  • 资助金额:
    $ 19.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Characterizing breast cancer invasion and proliferation when co-aggregated with adipocytes in multicellular spheroids created with a custom bioreactor to augment cell-cell connectivity.
当与多细胞球体中的脂肪细胞共聚集时,表征乳腺癌的侵袭和增殖,该多细胞球体是用定制生物反应器创建的,以增强细胞间的连接。
  • 批准号:
    10334113
  • 财政年份:
    2022
  • 资助金额:
    $ 19.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了